Adaptimmune Therapeutics 2024 Annual Report 10-K

Adaptimmune Therapeutics PLC's 2024 annual report filing with the SEC, covering fiscal year ended December 31, 2024. The company is a biopharmaceutical firm developing cell therapy treatments, headquartered in Abingdon, UK, trading on Nasdaq under ticker ADAP.